CU6
Clarity Pharmaceuticals Ltd
Pharmaceuticals
·
Healthcare
24
comments
8
fund managers
past 90 days
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company founded by Matthew Harris in 2010. Headquartered in Eveleigh, Australia, the firm specializes in the research, development, and clinical evaluation of a portfolio of novel radiopharmaceutical products. As a clinical-stage entity, Clarity Pharmaceuticals focuses on advancing its pipeline to address unmet needs in diagnostic and therapeutic oncology through innovative radiopharmaceutical technology.
Commentary Volume
24
Comments
8
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$938M
Fund managers
8 managers
First covered
31 Aug 2023
Last updated
28 Feb 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Clarity Pharmaceuticals Ltd (ASX:CU6)
Frequently asked questions
Who is investing in Clarity Pharmaceuticals Ltd (ASX:CU6)?
Fund managers including Frazis Capital Partners, Pengana Capital Group, SG Hiscock & Company, Endeavor Asset Management, Ausbil Investment Management, Blackwattle Investment Partners, Pengana Capital and Perennial Partners have invested in Clarity Pharmaceuticals Ltd (ASX:CU6).
What is the short interest in Clarity Pharmaceuticals Ltd (ASX:CU6)?
The short interest in Clarity Pharmaceuticals Ltd (ASX:CU6) is 6.07% which makes it the 31st most shorted stock on the ASX. Of the 372.0M shares that Clarity Pharmaceuticals Ltd has on issue, 22.6M have been sold short.
What does Clarity Pharmaceuticals Ltd (ASX:CU6) do?
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company founded by Matthew Harris in 2010. Headquartered in Eveleigh, Australia, the firm specializes in the research, development, and clinical evaluation of a portfolio of novel radiopharmaceutical products. As a clinical-stage entity, Clarity Pharmaceuticals focuses on advancing its pipeline to address unmet needs in diagnostic and therapeutic oncology through innovative radiopharmaceutical technology.
Loading...